2 terminated, 1 completed, 1 recruiting. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Completed 1, Recruiting 1 |
Follow Protein Kinase Inhibitors: new trials by email Literature Review of Protein Kinase Inhibitors trials Research Report on Protein Kinase Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors JYP0322 50 mg qd, JYP0322 100 mg qd, JYP0322 200 mg qd - Protein Kinase Inhibitors, Other Protocol Specified Criteria | Phase 1 | Recruiting | Guangzhou JOYO Pharma Co., Ltd | 101 | 2022-05-04 | 2025-07-14 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. JNJ-26483327 - Protein Kinase Inhibitors, Antineoplastic Protocols | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 19 | 2006-08-01 | 2010-04-26 |
Lung Neoplasms (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Nerve Tissue (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Brain Neoplasms (1)
Bronchial Diseases (2) · Neoplasms, Glandular and Epithelial (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
osimertinib (2) · BID protein, human (1) · Carboplatin (1) · JNJ-26483327 (1) · Pemetrexed (1)
Blueprint Medicines Corporation (2) · Guangzhou JOYO Pharma Co., Ltd (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)
United States (2) · Canada (1) · China (1) · France (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Li Zhang, M.D. (1)